- Home
- FUTU vs NBIX Comparison
FUTU vs NBIX Comparison
Compare FUTU & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUTU
- NBIX
- Stock Information
- Founded
- FUTU 2011
- NBIX 1992
- Country
- FUTU Hong Kong
- NBIX United States
- Employees
- FUTU N/A
- NBIX N/A
- Industry
- FUTU Investment Bankers/Brokers/Service
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FUTU Finance
- NBIX Health Care
- Exchange
- FUTU Nasdaq
- NBIX Nasdaq
- Market Cap
- FUTU 11.6B
- NBIX 13.1B
- IPO Year
- FUTU 2019
- NBIX 1996
- Fundamental
- Price
- FUTU $85.80
- NBIX $138.71
- Analyst Decision
- FUTU Buy
- NBIX Buy
- Analyst Count
- FUTU 6
- NBIX 23
- Target Price
- FUTU $76.50
- NBIX $165.00
- AVG Volume (30 Days)
- FUTU 2.6M
- NBIX 884.4K
- Earning Date
- FUTU 11-19-2024
- NBIX 02-05-2025
- Dividend Yield
- FUTU N/A
- NBIX N/A
- EPS Growth
- FUTU 2.20
- NBIX 97.40
- EPS
- FUTU 4.09
- NBIX 3.73
- Revenue
- FUTU $1,307,165,497.00
- NBIX $2,242,800,000.00
- Revenue This Year
- FUTU $36.79
- NBIX $27.07
- Revenue Next Year
- FUTU $17.27
- NBIX $16.60
- P/E Ratio
- FUTU $20.17
- NBIX $36.67
- Revenue Growth
- FUTU 11.68
- NBIX 25.72
- 52 Week Low
- FUTU $43.61
- NBIX $110.95
- 52 Week High
- FUTU $130.50
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- FUTU 48.50
- NBIX 73.61
- Support Level
- FUTU $81.40
- NBIX $125.61
- Resistance Level
- FUTU $86.93
- NBIX $130.48
- Average True Range (ATR)
- FUTU 3.99
- NBIX 2.67
- MACD
- FUTU 0.10
- NBIX 0.90
- Stochastic Oscillator
- FUTU 22.45
- NBIX 95.47
About FUTU Futu Holdings Limited
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.